for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Ekso Bionics Holdings Inc

EKSO.O

Latest Trade

8.85USD

Change

1.51(+20.57%)

Volume

1,992,428

Today's Range

7.26

 - 

9.21

52 Week Range

2.25

 - 

19.65

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
7.34
Open
7.40
Volume
1,992,428
3M AVG Volume
62.82
Today's High
9.21
Today's Low
7.26
52 Week High
19.65
52 Week Low
2.25
Shares Out (MIL)
7.59
Market Cap (MIL)
67.18
Forward P/E
-4.25
Dividend (Yield %)
--

Latest Developments

More

Ekso Bionics Holdings Files For Mixed Shelf Of Upto $75 Mln

Ekso Bionics Announces CFIUS Determination Regarding China Joint Venture

Ekso Bionics To Reduce Workforce By Approximately 35%

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Ekso Bionics Holdings Inc

Ekso Bionics Holdings, Inc., formerly PN Med Group, Inc., designs, develops and sells wearable bionic human exoskeletons that have applications in healthcare, industrial, military and consumer markets. The Company operates through two segments: Engineering Services and Medical. The Engineering Services segment is engaged in collaborative research and development service arrangements, technology license agreements and government grants where it uses its robotics domain knowledge in bionic exoskeletons to bid on and procure contracts and grants from entities, such as the National Science Foundation and the Defense Advanced Research Projects Agency. The Medical segment designs, engineers and manufactures exoskeletons for applications in the medical and military markets. The Company's exoskeleton systems are worn over the user's clothing. The exoskeleton systems serve various markets, which can be used both by able-bodied users, as well as by persons with physical disabilities.

Industry

Medical Equipment & Supplies

Contact Info

1414 Harbour Way S Ste 1201

RICHMOND, CA

94804-3628

United States

+1.510.9841761

https://ir.eksobionics.com/

Executive Leadership

Steven A. Sherman

Executive Chairman of the Board

Jack Peurach

President, Chief Executive Officer, Director

John F. Glenn

Chief Financial Officer, Secretary

William R. Shaw

Chief Commercial Officer

Theodore T. Wang

Director

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-13.800

2018

-6.900

2019

-2.550

2020(E)

-2.080
Price To Earnings (TTM)
--
Price To Sales (TTM)
5.71
Price To Book (MRQ)
9.89
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
41.51
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-79.00
Return on Equity (TTM)
-42.93

Latest News

Latest News

BRIEF-Ekso Bionics Gets FDA Clearance To Market Eksonr Robotic Exoskeleton

* EKSO BIONICS® RECEIVES FDA CLEARANCE TO MARKET ITS EKSONR™ ROBOTIC EXOSKELETON FOR USE WITH ACQUIRED BRAIN INJURY PATIENTS Source text for Eikon: Further company coverage:

BRIEF-Ekso Bionics Holdings Files For Mixed Shelf Of Upto $75 Mln

* EKSO BIONICS HOLDINGS INC FILES FOR MIXED SHELF OF UPTO $75 MILLION - SEC FILING Source: (https://bit.ly/2YIlMgb) Further company coverage:

BRIEF-Ekso Bionics Announces $7.89 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

* EKSO BIONICS ANNOUNCES $7.89 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES

BRIEF-Ekso Bionics Announces CFIUS Determination Regarding China Joint Venture

* EKSO BIONICS ANNOUNCES CFIUS DETERMINATION REGARDING CHINA JOINT VENTURE

BRIEF-Ekso Bionics To Reduce Workforce By Approximately 35%

* EKSO BIONICS HOLDINGS INC - IMPLEMENTED A PLAN TO REDUCE ITS WORKFORCE BY APPROXIMATELY 35%

BRIEF-Ekso Bionics Holdings - Entered Into An Unsecured Note Evidencing A $1.1 Mln Unsecured Loan

* EKSO BIONICS HOLDINGS - ENTERED INTO AN UNSECURED NOTE EVIDENCING AN UNSECURED LOAN IN AMOUNT OF $1.1 MILLION UNDER PAYCHECK PROTECTION PROGRAM Source text: (https://bit.ly/354Dc9F) Further company coverage:

BRIEF-Ekso Bionics To Report Q1 Financial Results On April 30

* EKSO BIONICS® TO REPORT FIRST QUARTER 2020 FINANCIAL RESULTS ON APRIL 30, 2020 Source text for Eikon: Further company coverage:

BRIEF-Ekso Bionics Says COVID-19 Has Caused Order Delays

* EKSO BIONICS PROVIDES COVID-19 BUSINESS UPDATE AND REPORTS PRELIMINARY FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-Ekso Bionics® Announces Reverse Stock Split

* EKSO BIONICS HOLDINGS INC - WILL EFFECT A REVERSE STOCK SPLIT OF SHARES OF ITS COMMON STOCK AT A RATIO OF 1-FOR-15 Source text for Eikon: Further company coverage:

BRIEF-Ekso Bionics Stockholders Approve Reverse Stock Split

* EKSO BIONICS HOLDINGS - STOCKHOLDERS APPROVED REVERSE STOCK SPLIT OF CO'S COMMON STOCK AT RATIO OF NOT LESS THAN 1-FOR-5 & NOT MORE THAN 1-FOR-15 Source text: (http://bit.ly/38ZPPmK) Further company coverage:

BRIEF-Puissance Cross-Border Opportunities Reports A Stake Of 13.3% In Ekso Bionics

* PUISSANCE CROSS-BORDER OPPORTUNITIES II LLC REPORTS A STAKE OF 13.3% IN EKSO BIONICS HOLDINGS INC AS OF MAR 4 - SEC FILING

BRIEF-Ekso Bionics Q1 Loss Per Share $0.13

* Q1 REVENUE ROSE 75 PERCENT TO $2.5 MILLION Source text for Eikon: Further company coverage:

BRIEF-Ekso Bionics Holdings Q4 Revenue $2.5 Million

* EKSO BIONICS REPORTS FOURTH QUARTER AND YEAR END 2017 RESULTS

BRIEF-Ekso Bionics Announces Executive Leadership Changes

* EKSO BIONICS ANNOUNCES EXECUTIVE LEADERSHIP CHANGES; JACK PEURACH, CO-FOUNDER OF EKSO BIONICS, LONG-TIME BOARD MEMBER AND SEASONED EXECUTIVE APPOINTED PRESIDENT AND CHIEF EXECUTIVE OFFICER; CHARLES LI, PH. D. TO JOIN BOARD OF DIRECTORS

BRIEF-Ekso Bionics To Expand Clinical Trial Sites For Comparative Multicenter WISE Study

* EKSO BIONICS® TO EXPAND CLINICAL TRIAL SITES FOR COMPARATIVE MULTICENTER WISE STUDY

BRIEF-Ekso Bionic Partners With HASOMED To Launch Functional Electrical Stimulation For The EksoGT Exoskeleton

* EKSO BIONICS HOLDINGS INC - LAUNCH OF EKSOGT EXOSKELETON'S FUNCTIONAL ELECTRICAL STIMULATION INTERFACE CAPABILITY THROUGH A PARTNERSHIP WITH HASOMED Source text for Eikon: Further company coverage:

Ford, Ekso team up for 'bionic' auto workers

Robots have replaced many U.S. manufacturing workers, but new mechanical exoskeletons being tested by Ford Motor Co <F.N> may help factory workers to function like bionic people, reducing the physical damage of millions of repetitive tasks over many years.

BRIEF-Ekso Bionics holdings Q3 loss per share $0.18

* Q3 revenue $1.6 million Source text for Eikon: Further company coverage:

BRIEF-Ekso Bionics Holdings files for stock shelf of up to $25.7 mln

* Ekso bionics holdings inc files for stock shelf of up to $25.7 million – sec filing Source text for Eikon: (http://bit.ly/2y233AA) Further company coverage:

BRIEF-Ekso Bionics appoints Ted Wang to its board of directors

* Ekso Bionics Holdings Inc - wang will replace Dan Boren, who joined Ekso board in April 2013 and resigned effective September 19, 2017 Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up